Complete report $1,850. Individual company assessments $250. Each company's analysis provides: - U.S. and international sales and operating profit estimates by division, geographic region, therapeutic category, and individual drug.
- Five-year sales and operating profit performance.
The companies analyzed in the report: - Abbott
- AstraZeneca
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson
- Merck
- Novartis
- Pfizer
- Roche
- Sanofi-Aventis Contains 130 pages and 92 tables
|